Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
Swiss rare diseases specialist Santhera Pharmaceuticals has appointed Shabir Hasham as chief medical officer (CMO) and a member of its executive management team, effective May 1. 13 April 2022
California-based biotech Eikon Therapeutics announced the appointment of Kenneth Frazier as an independent director effective April 1, 2022. 1 April 2022
Alector, a Californian company pursuing an immunological approach to targeting neurological conditions, has appointed a new chief medical officer. 30 March 2022
Californian gene specialist Mammoth Biosciences, a three-year old biotech focused on developing CRISPR products, has made a new senior executive appointment. 24 March 2022
Arenaviral immunotherapies company Hookipa Pharma has announced that Klaus Orlinger has been promoted to the role of chief scientific officer (CSO). 23 March 2022
Metagenomi, a California, USA-based genetic medicines company with a versatile portfolio of next-generation gene editing tools, today announced the appointment of Christine Foster, as chief business officer and Alan Cohen, as chief medical officer and senior vice president of Monogenic Diseases. 15 March 2022
Privately-held US biotech Teon Therapeutics has announced the appointment of Serge Messerlian as chief executive and member of the board of directors. 9 March 2022
California, USA-based clinical-stage biotech CODA Biotherapeutics, which is focussed on neurological disorders, has appointed Susan Catalano as chief scientific officer. 9 March 2022
UK and USA-based clinical-stage biopharmaceutical company F-star Therapeutics has appointed James Sandy as chief development officer (CDO), effective March 1. 2 March 2022
Spark Therapeutics, fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease that was acquired by Swiss pharma giant Roche (ROG: SIX) in a $4.8 billion deal in 2020, today announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey Marrazzo as chief executive. 23 February 2022
French immunotherapeutics-focussed biotech firm Transgene has appointed Steven Bloom as vice president, chief business officer with immediate effect. 10 February 2022
New Jersey-based Outlook Therapeutics, a biopharma company working to develop and launch the first approved ophthalmic formulation of bevacizumab for use in retinal indications, has announced the appointment of Joel Prieve as senior vice president, Commercial Operations. 8 February 2022
Shares of Finnish clinical-stage biopharma Faron Pharmaceutical were up 4.7% at 254 pence this morning as it announced the appointment of Juho Jalkanen as chief operating officer of the company. 31 January 2022
UK gene and cell therapy group Oxford Biomedica and US genetic medicines company Homology Medicines have agreed to establish a high-performing, full scope adeno-associated virus (AAV) manufacturing and innovation business in the USA. 28 January 2022
Replacing its retiring co-founder and chief executive Onno van de Stolpe, Belgium-based biotech Galapagos today announced that industry veteran Paul Stoffels will join the company as CEO effective April 1. 27 January 2022
Austrian drug developer Marinomed Biotech today announced the appointment of Dr Cornelia Kutzer as chief business officer (CBO) of the company. 21 January 2022
New biotech company Altos Labs has launched today with the aim of unraveling the deep biology of cellular rejuvenation programming, with $3 billion fully committed from renowned company builders and investors. 19 January 2022
Polish biotech Ryvu Therapeutics has announced the appointment of Dr Hendrik Nogai to the role of chief medical officer effective February 1, 2022. 17 January 2022